Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients.

Auli Verkkoniemi-AholaPäivi HartikainenKatja HassiHanna Kuusisto Sanni LahdenperäJuha MehtäläMatias ViitalaTero Ylisaukko-OjaMerja Soilu-Hänninen

Published in: Multiple sclerosis journal - experimental, translational and clinical (2023)

Treatment persistence was very high among John Cunningham virus negative patients. The study supports long-term effectiveness of natalizumab and a washout duration of less than 6 weeks after discontinuation.

Keyphrases

multiple sclerosis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
peritoneal dialysis
prognostic factors
systematic review